EMEA-001760-PIP01-15-M03

Key facts

Invented name	Lartruvo
Active substance	Olaratumab
Therapeutic area	Oncology
Decision number	P/0112/2019
PIP number	EMEA-001760-PIP01-15-M03
Pharmaceutical form(s)	Concentrate for solution for infusion
Condition(s) / indication(s)	Treatment of osteosarcoma Treatment of soft tissue sarcoma
Route(s) of administration	Intravenous use
Contact for public enquiries	Eli Lilly & Company Limited E-mail: eu_paediatric@lilly.com Tel. +44 (0)1276 483000
Decision type	W: decision granting a waiver in all age groups for all conditions or indications

Decision

List item

P/0112/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan and on granting of a waiver in condition for treatment of soft tissue sarcoma for olaratumab (Lartruvo), (EMEA-001760-PIP01-15-M03) (PDF/222.53 KB)

Adopted

First published: 24/06/2019
EMA/170135/2019

Related content

List item

Olaratumab - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision (PDF/91.02 KB)

First published: 08/10/2021

How useful was this page?

Add your rating

★ ★ ★ ★ ★